Point72 Takes 5.1% Stake in C4 Therapeutics

TL;DR

**Point72 just bought 5.1% of C4 Therapeutics, big institutional vote of confidence!**

AI Summary

Point72 Asset Management, L.P. has disclosed a significant stake in C4 Therapeutics, Inc., beneficially owning 2,312,059 shares of common stock as of January 3, 2024. This represents a 5.1% ownership of the biotech company, indicating a notable investment by a major hedge fund. This matters to investors because it signals a vote of confidence from a sophisticated institutional investor, potentially attracting more attention and capital to C4 Therapeutics.

Why It Matters

A major hedge fund like Point72 buying over 5% of C4 Therapeutics suggests they see significant upside, which could boost investor confidence and potentially the stock price.

Risk Assessment

Risk Level: low — This filing indicates a significant institutional investment, generally seen as a positive signal rather than a risk.

Analyst Insight

A smart investor would view this as a positive signal, potentially researching C4 Therapeutics further to understand Point72's investment thesis and consider adding the stock to their watchlist or portfolio.

Key Numbers

• 2,312,059 — Shares Beneficially Owned (Represents the total number of C4 Therapeutics shares Point72 Asset Management, L.P. has shared voting and dispositive power over.)
• 5.1% — Ownership Percentage (The aggregate amount beneficially owned by Point72 Asset Management, L.P. relative to C4 Therapeutics' outstanding shares.)

Key Players & Entities

• Point72 Asset Management, L.P. (company) — the reporting person and institutional investor
• C4 Therapeutics, Inc. (company) — the subject company whose shares were acquired
• Delaware (company) — place of organization for Point72 Asset Management, L.P.
• January 3, 2024 (date) — date of the event requiring the filing
• $0.0001 (dollar_amount) — par value per share of C4 Therapeutics Common Stock

Forward-Looking Statements

• C4 Therapeutics' stock price may experience increased trading volume and positive sentiment due to institutional interest. (C4 Therapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• p24-0025sc13g.htm (SC 13G) — 74KB
• p24-0025exhibit99.htm (EX-99) — 8KB
• 0000902664-24-000047.txt ( ) — 83KB

(a)

Item 1(a). Name of Issuer. C4 Therapeutics, Inc.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 490 Arsenal Way, Suite 120, Watertown, Massachusetts 02472

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to shares of common stock, par value $0.0001 per share (" Shares "), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc .") with respect to Shares held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (" Cubist Systematic Strategies ") with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (" Mr. Cohen ") with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Common Stock, par value $0.0001 per share

(e)

Item 2(e). CUSIP Number. 12529R107 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on January 3, 2024. CUSIP No. 12529R107 13G Page 7 of 8 Pages Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by a certain investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. See Item 2(a). Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable. Item

View Full Filing

View this SC 13G filing on SEC EDGAR